
In July 2003, the Food and Drug Administration (FDA) authorized pharmaceutical companies to promote human Growth Hormone (hGH) for use in children who are very short but not suffering from any specific illness or medical condition. Parents are now using hGH in record numbers, hoping that hormone treatment will give their kids happier childhoods and more prosperous adulthoods. No one should doubt these parental good intentions. But the normalization of height enhancement reflects a troubling disposition, familiar in our time, to redefine disadvantageous traits as illnesses and look to medical techniques for a cure. Of course, there are often real benefits to using medical technologies for self-improvement: straighter teeth, clearer complexions, firmer figures. Our technological enhancements to body and psyche, however, may also undermine those human goods that are less obvious but more fundamental - especially parental love for the abnormal child and civic love for the abnormal neighbor. We can hardly expect the FDA, under that agency's current mission, to worry about such matters; its concern is the safety of products, not the health of the culture. But when it approved height enhancement for healthy kids, the FDA made a mistake on our behalf. Exploring the nature of this error may help us deal more wisely with the enhancements of the future, or at least see more clearly the full meaning of our improvements.
Copyright 2006. All rights reserved. See www.TheNewAtlantis.com for more information. In the debate about the moral standing of human embryos, some defenders of embryo-destructive research have claimed that human embryos are not human beings until implantation (i.e., when the embryo attaches to the uterus, approximately six days after fertilization), and others have claimed that they are not human beings until gastrulation (i.e., when the possibility of twinning no longer exists and the primitive neural streak first appears, approximately 14 days after fertilization). These claims have been repeated by policymakers, scientists, and bioethicists alike, yet they fly in the face of the embryological evidence. Seeing why will put the embryo research debate on a more solid biological footing.
In many realms of life there are questions that never really go away. We address them more or less satisfactorily, and, for a time, they recede from the center of our attention. Yet, because they are important, they are likely to reappear and again demand our consideration. In the realm of bioethics one such question is whether it could be right to increase the supply of organs for transplant by providing financial incentives for those who supply their organs or, even, by establishing some kind of market for the sale of organs. (Whether the market should work only for sellers or for buyers also is, of course, one aspect of this recurring issue.) Such questions have received attention in the past, but in recent years—fueled by longer waiting lists for transplantation—they have returned to the center of bioethical concern. In May, 2006, the Institute of Medicine (IOM) released a report (titled, Organ Donation: Opportunities for Action) that recommended against using financial incentives to boost organ supply. The report did, however, propose some other means aimed at achieving the same goal—in particular, increasing the rate of organ procurement from those who die suddenly of cardiac arrest. On May 15, 2006, responses to this report appeared on the op-ed pages of both the New York Times and the Wall Street Journal. Sally Satel (in the Times) and Richard Epstein (in the Journal) attacked the IOM report for its “timid,” “narrowminded,” and “unimaginative” thinking. “The key lesson in all this,” wrote Epstein, “is that we should look with deep suspicion on any blanket objection to market incentives—especially from high-minded moralists who have convinced themselves that their aesthetic sensibilities and instinctive revulsion should trump any humane efforts to save lives.” Although this is a serious challenge, it is, I think, a forgetful and a misleading one. Forgetful, because it has lost contact with the reasons that moved our society to turn to an organ procurement system based on giving (even if for a variety of motives, not all of which need be altruistic). Misleading, because in its animus against moralism it adopts a too simple moral position for which saving of lives always has trump. The questions that need asking are not aesthetic but anthropological, and it would be a shame if we were to become tone deaf to such questions, however difficult to articulate they may be. So, for instance, we must ask: Even Gifts of the Body Gilbert Meilaender
Copyright 2006. All rights reserved. See www.TheNewAtlantis.com for more information. Over the past fifty years, several pivotal advances have transformed the life sciences, including the discovery of the structure of DNA, the deciphering of the genetic code, the development of recombinant DNA technology, and the mapping of the human genome. Synthetic biology is another transformative innovation that will make it possible to build living machines from off-the-shelf chemical ingredients, employing many of the same strategies that electrical engineers use to make computer chips. Drawing upon a set of powerful techniques for the automated synthesis of DNA molecules and their assembly into genes and microbial genomes, synthetic biology envisions the redesign of natural biological systems for greater efficiency, as well as the construction of functional “genetic circuits” and metabolic pathways for practical purposes. Among the potential applications of this new field is the creation of bioengineered microorganisms (and possibly other life forms) that can produce pharmaceuticals, detect toxic chemicals, break down pollutants, repair defective genes, destroy cancer cells, and generate hydrogen for the postpetroleum economy. Although synthetic biology is chiefly an engineering discipline, the ability to design and construct simplified biological systems offers life scientists a useful way to test their understanding of the complex functional networks of genes and biomolecules that mediate life processes. Today, synthetic biology is at roughly the same level of development as molecular genetics was in the midto late 1970s, some five years after the invention of recombinant-DNA technology. In June 2004, the first international conference devoted to the new field, “Synthetic Biology 1.0,” was held at the Massachusetts Institute of Technology (M.I.T.). The organizers